Zealand Pharma A/S (OTCMKTS:ZLDPF) Releases Quarterly Earnings Results

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its earnings results on Thursday. The company reported $8.61 EPS for the quarter, topping the consensus estimate of ($0.42) by $9.03, Zacks reports. The firm had revenue of $698.62 million for the quarter, compared to analysts’ expectations of $686.54 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.80%.

Zealand Pharma A/S Price Performance

Zealand Pharma A/S stock remained flat at $52.68 during trading on Friday. The company had a trading volume of 180 shares, compared to its average volume of 321. Zealand Pharma A/S has a fifty-two week low of $35.93 and a fifty-two week high of $83.12. The company has a debt-to-equity ratio of 0.02, a quick ratio of 37.17 and a current ratio of 37.17. The company’s 50-day moving average price is $45.63 and its 200 day moving average price is $49.46. The firm has a market cap of $3.77 billion, a PE ratio of 3.91 and a beta of 0.88.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ZLDPF. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Berenberg Bank lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Wolfe Research cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.